FR14C0080I2 - Methode d'administration d'un anticorps - Google Patents

Methode d'administration d'un anticorps

Info

Publication number: FR14C0080I2
Authority: FR; France
Prior art keywords: antibody administration; antibody; administration
Prior art date: 2000-04-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR14C0080C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Genentech Inc

Millennium Pharmaceuticals Inc

Original Assignee

Genentech Inc

Millennium Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-14

Filing date

2014-11-13

Publication date

2015-10-30

2014-11-13 Application filed by Genentech Inc, Millennium Pharmaceuticals Inc filed Critical Genentech Inc

2014-12-19 Publication of FR14C0080I1 publication Critical patent/FR14C0080I1/fr

2015-10-30 Application granted granted Critical

2015-10-30 Publication of FR14C0080I2 publication Critical patent/FR14C0080I2/fr

Status Active legal-status Critical Current

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]

FR14C0080C 2000-04-14 2014-11-13 Methode d'administration d'un anticorps Active FR14C0080I2 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US55008200A	2000-04-14	2000-04-14
US09/748,960 US20010046496A1 (en)	2000-04-14	2000-12-27	Method of administering an antibody
PCT/US2001/012234 WO2001078779A2 (fr)	2000-04-14	2001-04-13	Methode d'administration d'un anticorps

Publications (2)

Publication Number	Publication Date
FR14C0080I1 FR14C0080I1 (fr)	2014-12-19
FR14C0080I2 true FR14C0080I2 (fr)	2015-10-30

Family

ID=27069332

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR14C0080C Active FR14C0080I2 (fr)	2000-04-14	2014-11-13	Methode d'administration d'un anticorps

Country Status (16)

Country	Link
US (5)	US20010046496A1 (fr)
EP (3)	EP1278543B1 (fr)
JP (3)	JP2003531129A (fr)
AU (1)	AU2001251629A1 (fr)
BE (1)	BE2017C009I2 (fr)
CA (1)	CA2406220C (fr)
CY (3)	CY1113489T1 (fr)
DK (2)	DK1278543T3 (fr)
ES (2)	ES2609689T3 (fr)
FR (1)	FR14C0080I2 (fr)
HK (1)	HK1054320A1 (fr)
LU (1)	LUC00014I2 (fr)
MX (1)	MXPA02010059A (fr)
NL (1)	NL300702I2 (fr)
PT (1)	PT2298348T (fr)
WO (1)	WO2001078779A2 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7658924B2 (en)	2001-10-11	2010-02-09	Amgen Inc.	Angiopoietin-2 specific binding agents
US7521053B2 (en)	2001-10-11	2009-04-21	Amgen Inc.	Angiopoietin-2 specific binding agents
MY157727A (en) *	2002-02-25	2016-07-15	Biogen Idec Inc	Administration of agents for the treatment of inflamation
GB0210121D0 (en)	2002-05-02	2002-06-12	Celltech R&D Ltd	Biological products
ES2916174T3 (es) *	2002-05-02	2022-06-28	Wyeth Holdings Llc	Conjugados de transportador derivado de caliqueamicina
PE20051053A1 (es)	2004-01-09	2005-12-12	Pfizer	ANTICUERPOS CONTRA MAdCAM
PT2990422T (pt) *	2004-09-03	2018-10-18	Genentech Inc	Antagonistas humanizados anti-beta7 e suas utilizações
EP1904531B1 (fr)	2005-07-08	2010-10-06	Pfizer Limited	Anticorps anti-madcam
WO2007007152A2 (fr) *	2005-07-11	2007-01-18	Pfizer Limited	Anticorps anti-madcam utilises pour le traitement de cancers metastatiques et du chlorome
WO2007007162A1 (fr) *	2005-07-11	2007-01-18	Pfizer Limited	Nouvelle combinaison d'un anticorps anti-madcam et d'un inhibiteur de caspase anti-fibrotique pour le traitement de la fibrose du foie
AU2008204433B2 (en) *	2007-01-11	2014-03-13	Novo Nordisk A/S	Anti-KIR antibodies, formulations, and uses thereof
JP2010521966A (ja) *	2007-03-20	2010-07-01	ミレニアム・ファーマシューティカルズ・インコーポレイテッド	α４β７インテグリンに結合するヒト化免疫グロブリンをコードする核酸
US20110105724A1 (en) *	2007-08-16	2011-05-05	Stephanie Jane Clegg	Novel compounds
JO2913B1 (en)	2008-02-20	2015-09-15	امجين إنك,	Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US20100255508A1 (en) *	2008-05-16	2010-10-07	Thomas Richard Gelzleichter	Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
TWI477511B (zh) *	2009-03-20	2015-03-21	Amgen Inc	α4β7雜二聚體專一性拮抗抗體
EP3578205A1 (fr)	2010-08-06	2019-12-11	ModernaTX, Inc.	Compositions pharmaceutiques a base d'acides nucléiques modifiés et leur utilisation medicale
CA3162352A1 (fr)	2010-10-01	2012-04-05	Modernatx, Inc.	Nucleosides, nucleotides et acides nucleiques modifies, et utilisations connexes
DE12722942T1 (de)	2011-03-31	2021-09-30	Modernatx, Inc.	Freisetzung und formulierung von manipulierten nukleinsäuren
LT2704742T (lt) *	2011-05-02	2017-10-25	Millennium Pharmaceuticals, Inc.	Anti-alfa4beta7 antikūno kompozicija
UA116189C2 (uk) *	2011-05-02	2018-02-26	Мілленніум Фармасьютікалз, Інк.	КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
US9464124B2 (en)	2011-09-12	2016-10-11	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
PT3682905T (pt)	2011-10-03	2022-04-07	Modernatx Inc	Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
CA2856866C (fr) *	2011-11-23	2022-07-12	Amgen Inc.	Administration d'un anticorps specifique heterodimere anti-alpha-4-beta-7
LT2791160T (lt)	2011-12-16	2022-06-10	Modernatx, Inc.	Modifikuotos mrnr sudėtys
EA201992881A3 (ru) *	2012-01-12	2020-12-30	Милленниум Фармасьютикалз, Инк.	Композиция анти-47 антитела
US9303079B2 (en)	2012-04-02	2016-04-05	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en)	2012-04-02	2016-03-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en)	2012-04-02	2017-02-21	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
CA2868996A1 (fr)	2012-04-02	2013-10-10	Moderna Therapeutics, Inc.	Polynucleotides modifies pour la production de proteines
PL2922554T3 (pl)	2012-11-26	2022-06-20	Modernatx, Inc.	Na zmodyfikowany na końcach
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
EP3052106A4 (fr)	2013-09-30	2017-07-19	ModernaTX, Inc.	Polynucléotides codant des polypeptides de modulation immunitaire
JP2016538829A (ja)	2013-10-03	2016-12-15	モデルナセラピューティクスインコーポレイテッドＭｏｄｅｒｎａＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	低密度リポタンパク質受容体をコードするポリヌクレオチド
EP3581585A1 (fr)	2014-11-26	2019-12-18	Millennium Pharmaceuticals, Inc.	Vedolizumab pour le traitement de la fistulisation de la maladie de crohn
JP6904905B2 (ja)	2014-12-24	2021-07-21	ミレニアムファーマシューティカルズ，インコーポレイテッドＭｉｌｌｅｎｎｉｕｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	抗α４β７インテグリン抗体による治療の結果の予測
IL261750B1 (en)	2016-03-14	2024-03-01	Millennium Pharm Inc	A method for preventing graft-versus-host disease
AU2017234010A1 (en)	2016-03-14	2018-09-27	Millennium Pharmaceuticals, Inc.	Methods of treating or preventing graft versus host disease
WO2017165778A1 (fr)	2016-03-24	2017-09-28	Millennium Pharmaceuticals, Inc.	Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires
WO2017165742A1 (fr)	2016-03-24	2017-09-28	Millennium Pharmaceuticals, Inc.	Procédés de traitement d'événements indésirables liés à l'immunité gastro-intestinale dans des polythérapies anti-ctla4 et anti-pd-1
EP3452070A1 (fr)	2016-05-04	2019-03-13	Millennium Pharmaceuticals, Inc.	Trithérapie pour le traitement d'une maladie intestinale inflammatoire
CN109414502A (zh)	2016-06-12	2019-03-01	千禧制药公司	治疗炎症性肠病的方法
SG11202000298VA (en)	2017-07-14	2020-02-27	Pfizer	Antibodies to madcam
US20230139938A1 (en) *	2021-09-21	2023-05-04	University Of South Carolina	Anti-CCL8 Antibodies and Treatment of Lung Injury by CCL8 Inhibition

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4172124A (en)	1978-04-28	1979-10-23	The Wistar Institute	Method of producing tumor antibodies
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
EP0307434B2 (fr) *	1987-03-18	1998-07-29	Scotgen Biopharmaceuticals, Inc.	Anticorps alteres
ATE120761T1 (de)	1987-05-21	1995-04-15	Creative Biomolecules Inc	Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5403919A (en) *	1987-08-11	1995-04-04	Board Of Trustees Of The Leland Stanford Junior University Stanford University	Method to control leukocyte extravasation
US5538724A (en) *	1987-08-11	1996-07-23	The Board Of Trustees For The Leland Stanford Junior Univ.	Method of control leukocyte extravasation
JP3095168B2 (ja)	1988-02-05	2000-10-03	エル．モリソン，シェリー	ドメイン‐変性不変部を有する抗体
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5859205A (en) *	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
SG48759A1 (en)	1990-01-12	2002-07-23	Abgenix Inc	Generation of xenogenic antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
EP0519596B1 (fr)	1991-05-17	2005-02-23	Merck & Co. Inc.	Procédé pour réduire l'immunogénicité des domaines variables d'anticorps
JP4124480B2 (ja) *	1991-06-14	2008-07-23	ジェネンテック・インコーポレーテッド	免疫グロブリン変異体
WO1994004679A1 (fr)	1991-06-14	1994-03-03	Genentech, Inc.	Procede pour fabriquer des anticorps humanises
AU665025B2 (en)	1991-09-23	1995-12-14	Cambridge Antibody Technology Limited	Production of chimeric antibodies - a combinatorial approach
US5871734A (en) *	1992-01-13	1999-02-16	Biogen, Inc.	Treatment for asthma with VLA-4 blocking agents
US5932214A (en) *	1994-08-11	1999-08-03	Biogen, Inc.	Treatment for inflammatory bowel disease with VLA-4 blockers
EP0682529B2 (fr) *	1993-02-09	2005-12-28	Biogen Idec MA, Inc.	Anticorps pour le traitement du diabete insulino-dependent
DE614989T1 (de)	1993-02-17	1995-09-28	Morphosys Proteinoptimierung	Verfahren für in vivo Selektion von Ligandenbindende Proteine.
AU691811B2 (en)	1993-06-16	1998-05-28	Celltech Therapeutics Limited	Antibodies
US5840299A (en)	1994-01-25	1998-11-24	Athena Neurosciences, Inc.	Humanized antibodies against leukocyte adhesion molecule VLA-4
GB2292079B (en) *	1994-08-12	1998-07-15	Flexpharm Ltd	Coated prednisolone preparation for the treatment of inflamatory bowel disease
US6551593B1 (en) *	1995-02-10	2003-04-22	Millennium Pharmaceuticals, Inc.	Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US6015662A (en) *	1996-01-23	2000-01-18	Abbott Laboratories	Reagents for use as calibrators and controls
US7147851B1 (en) *	1996-08-15	2006-12-12	Millennium Pharmaceuticals, Inc.	Humanized immunoglobulin reactive with α4β7 integrin
EP2305027B1 (fr)	1996-12-03	2014-07-02	Amgen Fremont Inc.	Mammifères trangèniques obtenus par génie génétique contenant des loci des immunoglobulines humaines qui comprennent plusieurs régions de VH et de Vkappa, et anticorps aussi obtenus.
PT1113810E (pt) *	1998-09-14	2009-03-10	Univ Texas	Processos de tratamento de mieloma múltiplo e reabsorção óssea induzida por mieloma utilizando antagonistas da ligação do receptor de integrina

2000
- 2000-12-27 US US09/748,960 patent/US20010046496A1/en not_active Abandoned
2001
- 2001-04-13 EP EP01925028A patent/EP1278543B1/fr not_active Expired - Lifetime
- 2001-04-13 DK DK01925028.1T patent/DK1278543T3/da active
- 2001-04-13 PT PT100109974T patent/PT2298348T/pt unknown
- 2001-04-13 AU AU2001251629A patent/AU2001251629A1/en not_active Abandoned
- 2001-04-13 CA CA2406220A patent/CA2406220C/fr not_active Expired - Lifetime
- 2001-04-13 MX MXPA02010059A patent/MXPA02010059A/es active IP Right Grant
- 2001-04-13 JP JP2001576078A patent/JP2003531129A/ja not_active Withdrawn
- 2001-04-13 DK DK10010997.4T patent/DK2298348T3/en active
- 2001-04-13 EP EP16191558.2A patent/EP3167902B1/fr not_active Expired - Lifetime
- 2001-04-13 WO PCT/US2001/012234 patent/WO2001078779A2/fr active Application Filing
- 2001-04-13 ES ES10010997.4T patent/ES2609689T3/es not_active Expired - Lifetime
- 2001-04-13 EP EP10010997.4A patent/EP2298348B9/fr not_active Expired - Lifetime
- 2001-04-13 ES ES01925028T patent/ES2398096T3/es not_active Expired - Lifetime
2003
- 2003-07-29 HK HK03105456.3A patent/HK1054320A1/xx unknown
- 2003-12-15 US US10/735,863 patent/US20050095238A1/en not_active Abandoned
2011
- 2011-08-05 US US13/204,139 patent/US20120034243A1/en not_active Abandoned
2012
- 2012-05-02 JP JP2012105379A patent/JP5764524B2/ja not_active Expired - Lifetime
- 2012-12-18 CY CY20121101236T patent/CY1113489T1/el unknown
2014
- 2014-02-03 US US14/171,161 patent/US20140186345A1/en not_active Abandoned
- 2014-11-11 NL NL300702C patent/NL300702I2/nl unknown
- 2014-11-13 FR FR14C0080C patent/FR14C0080I2/fr active Active
- 2014-11-17 CY CY2014046C patent/CY2014046I1/el unknown
2015
- 2015-01-19 JP JP2015007655A patent/JP6021959B2/ja not_active Expired - Lifetime
2017
- 2017-01-05 CY CY20171100013T patent/CY1118429T1/el unknown
- 2017-04-11 LU LU00014C patent/LUC00014I2/fr unknown
- 2017-04-11 BE BE2017C009C patent/BE2017C009I2/nl unknown
2018
- 2018-11-02 US US16/179,157 patent/US20200002423A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP2012184241A (ja)	2012-09-27
CY1118429T1 (el)	2017-06-28
DK1278543T3 (da)	2013-01-14
LUC00014I2 (fr)	2017-06-19
EP3167902A1 (fr)	2017-05-17
CY2014046I2 (el)	2016-04-13
US20200002423A1 (en)	2020-01-02
EP1278543B1 (fr)	2012-09-19
LUC00014I1 (fr)	2017-04-18
NL300702I1 (fr)	2016-01-28
EP2298348B1 (fr)	2016-10-12
FR14C0080I1 (fr)	2014-12-19
US20140186345A1 (en)	2014-07-03
JP2003531129A (ja)	2003-10-21
EP2298348A1 (fr)	2011-03-23
EP2298348B9 (fr)	2017-02-15
BE2017C009I2 (fr)	2017-09-22
JP2015083603A (ja)	2015-04-30
EP3167902B1 (fr)	2020-07-29
US20050095238A1 (en)	2005-05-05
US20010046496A1 (en)	2001-11-29
AU2001251629A1 (en)	2001-10-30
EP1278543A2 (fr)	2003-01-29
HK1054320A1 (en)	2003-11-28
DK2298348T3 (en)	2017-01-30
CA2406220C (fr)	2019-02-12
WO2001078779A3 (fr)	2002-07-04
JP5764524B2 (ja)	2015-08-19
NL300702I2 (fr)	2016-01-28
US20120034243A1 (en)	2012-02-09
CY2014046I1 (el)	2016-04-13
CY1113489T1 (el)	2016-04-13
JP6021959B2 (ja)	2016-11-09
ES2609689T3 (es)	2017-04-21
ES2398096T3 (es)	2013-03-13
WO2001078779A2 (fr)	2001-10-25
CA2406220A1 (fr)	2001-10-25
MXPA02010059A (es)	2004-08-19
PT2298348T (pt)	2017-01-04

Publication	Publication Date	Title
FR14C0080I2 (fr)	2015-10-30	Methode d'administration d'un anticorps
CY2013011I1 (el)	2015-08-05	Μεθοδος χορηγησης διφωσφονικων
DE60121953D1 (de)	2006-09-14	Herstellungsverfahren von arzneizubereitungen
MA27126A1 (fr)	2005-01-03	3'PROMEDICAMENTS DE 2'-DESOXY- β-L-NUCLEOSIDES
PT1253932E (pt)	2005-07-29	Composicoes farmaceuticas de toxina botulinica
CY2014003I2 (el)	2015-12-09	Φαρμακοτεχνικες μορφες εχινοκανδινης που περιεχουν επιφανειοδραστικα που σχηματιζουν μικκυλιο
IS5245A (is)	1999-11-11	Lyfjablanda úr ómeprasól
NO20071303L (no)	2001-07-27	Farmasoytiske preparater
CY2007029I1 (el)	2009-11-04	Μεθοδος για την παρασκευη υποκατεστημενων οκτανοϋλ-αμιδιων
NO20025450L (no)	2002-11-14	Ny farmasöytisk sammensetning
IS6688A (is)	2003-01-16	Lyfjafræðilegar samsetningar af kólesterýl ester flutningspróteinhindrum
ID30590A (id)	2002-01-03	Celana sekali pakai jenis-celana pendek
ID30187A (id)	2001-11-15	Dongkrak jenis pantagraf
EE200200393A (et)	2003-10-15	Glüburiidi ravimkoostis
DE50104789D1 (de)	2005-01-13	Desodorierende Zubereitungen
EE200300218A (et)	2003-08-15	Latentse antitrombiin III valmistamise meetod
DE60126814D1 (de)	2007-04-05	Inhalation von stickoxid
ITBO20000446A0 (it)	2000-07-21	Unita' e metodo di trasferimento di spezzoni di sigaretta .
NO20010490D0 (no)	2001-01-29	Inhibisjon av ''graft-versus-host''-sykdom
FR2816843B1 (fr)	2006-10-27	Inhibiteurs de l'enzyme 5 alpha-reductase
DE60132362D1 (de)	2008-02-21	Herstellung von ultradünnwandigen cordierit-strukturen
DE60142051D1 (de)	2010-06-17	Herstellung von perfluorolefinen
FR2824092B1 (fr)	2004-04-09	Ensemble d'elements de construction
MA27184A1 (fr)	2005-01-03	Dosage d'anticorps anti-ingap
FR2822846B1 (fr)	2004-01-23	Procede de preparation et de selection d'anticorps